Published in Br J Cancer on January 01, 1998
Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology (1999) 3.06
The oral fluorinated pyrimidines. Invest New Drugs (2001) 0.92
Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. Br J Clin Pharmacol (1998) 0.90
The nm23-H1 gene as a predictor of sensitivity to chemotherapeutic agents in oesophageal squamous cell carcinoma. Br J Cancer (1999) 0.87
Integrative metabonomics as potential method for diagnosis of thyroid malignancy. Sci Rep (2015) 0.86
The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon α-2b therapy against advanced hepatocellular carcinoma. J Gastroenterol (2010) 0.86
Pharmacogenomics in colorectal cancer: the first step for individualized-therapy. World J Gastroenterol (2007) 0.80
Role of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expressions in gallbladder carcinoma. Surg Today (2012) 0.80
Tissue Metabonomic Phenotyping for Diagnosis and Prognosis of Human Colorectal Cancer. Sci Rep (2016) 0.78
Role of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA in intrahepatic cholangiocarcinoma. Surg Today (2011) 0.75
Dihydropyrimidine dehydrogenase in normal and malignant endometrium: relationship with cell proliferation and thymidine phosphorylase. Virchows Arch (2003) 0.75
Thymidine phosphorylase and dihydropyrimidine dehydrogenase expression levels in tumor and normal tissue specimens of T3 human colorectal carcinoma. Surg Today (2006) 0.75
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem (1976) 903.81
Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res (1995) 3.04
Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res (1987) 2.71
Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest (1996) 2.02
Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res (1997) 1.84
Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer (1991) 1.60
Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res (1992) 1.53
A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer (1994) 1.49
Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol (1995) 1.47
Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res (1985) 1.33
Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br J Clin Pharmacol (1996) 1.18
Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy. Clin Pharmacol Ther (1995) 1.17
A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency. J Inherit Metab Dis (1996) 1.16
Xenobiotic metabolising enzyme expression in colonic neoplasia. Gut (1993) 1.08
Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate. Anticancer Res (1986) 1.00
DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents? Br J Cancer (1995) 0.95
Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver. Clin Cancer Res (1996) 0.93
5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res (1994) 0.89
Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities. Am J Med (1995) 0.89
Decreased folylpolyglutamate synthetase expression: a novel mechanism of fluorouracil resistance. Cancer Res (1993) 0.84
Effect of modulators on 5-fluorouracil metabolite patterns in murine colon carcinoma determined by in vitro 19F nuclear magnetic resonance spectroscopy. Cancer Res (1994) 0.81
Potentiation of 5-fluorouracil efficacy by the dihydrouracil dehydrogenase inhibitor, 5-benzyloxybenzyluracil. Cancer Res (1994) 0.78
The in vivo induction of rat hepatic cytochrome P450-dependent enzyme activities and their maintenance in culture. Biochem Pharmacol (1990) 0.78
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol (2000) 16.83
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst (2000) 5.62
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol (2001) 5.25
Environment-sensitive hydrogels for drug delivery. Adv Drug Deliv Rev (2001) 5.06
Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res (1999) 3.24
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol (2000) 3.04
Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol (2001) 2.95
Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer (2000) 2.73
Matrix metalloproteinases in tumour invasion and metastasis. J Pathol (1999) 2.65
Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet (1991) 2.26
Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology (2001) 2.25
Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res (2000) 2.17
Rural and urban differences in stage at diagnosis of colorectal and lung cancers. Br J Cancer (2001) 2.12
Analysis of the circular dichroism spectrum of proteins using the convex constraint algorithm: a practical guide. Anal Biochem (1992) 2.07
Rural factors and survival from cancer: analysis of Scottish cancer registrations. Br J Cancer (2000) 1.97
Synthesis of superporous hydrogels: hydrogels with fast swelling and superabsorbent properties. J Biomed Mater Res (1999) 1.95
Large variations in Southern Hemisphere biomass burning during the last 650 years. Science (2010) 1.95
Functional antagonism between YY1 and the serum response factor. Mol Cell Biol (1992) 1.91
Characterization of functional domains within the multifunctional transcription factor, YY1. J Biol Chem (1995) 1.88
A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res (1995) 1.86
Ward design in relation to postoperative wound infection. I. Br Med J (1971) 1.85
Mouse down-regulated in adenoma (DRA) is an intestinal Cl(-)/HCO(3)(-) exchanger and is up-regulated in colon of mice lacking the NHE3 Na(+)/H(+) exchanger. J Biol Chem (1999) 1.84
Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer. Ann Oncol (2013) 1.83
Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol (2006) 1.81
Gastric retentive drug-delivery systems. Crit Rev Ther Drug Carrier Syst (1998) 1.81
Factors influencing time from presentation to treatment of colorectal and breast cancer in urban and rural areas. Br J Cancer (2004) 1.80
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol (2000) 1.77
The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics (1999) 1.76
The role of annexins in tumour development and progression. J Pathol (2008) 1.75
Postoperative chemoradiotherapy for gastric cancer. Ann Oncol (2003) 1.73
Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy. Br J Cancer (2005) 1.71
Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study. Am J Respir Crit Care Med (2000) 1.71
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer (2003) 1.70
The use of sterilised polyester mosquito net mesh for inguinal hernia repair in Ghana. Hernia (2008) 1.69
Connexin26 mutations associated with nonsyndromic hearing loss. Laryngoscope (2000) 1.69
Post-transcriptional regulation of the human transforming growth factor-beta 1 gene. J Biol Chem (1992) 1.68
Tumour markers of prognosis in colorectal cancer. Br J Cancer (1999) 1.68
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer (2006) 1.66
Association between hepatitis B virus infection and HLA-DR type in Korea. Hepatology (2000) 1.65
Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer. Br J Cancer (2006) 1.65
Gastric retention properties of superporous hydrogel composites. J Control Release (2000) 1.64
Characterisation and protein expression profiling of annexins in colorectal cancer. Br J Cancer (2007) 1.61
Synthesis and characterization of superporous hydrogel composites. J Control Release (2000) 1.61
EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. Eur J Cancer (1996) 1.58
Protein adsorption on polymer surfaces: calculation of adsorption energies. J Biomater Sci Polym Ed (1990) 1.58
Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res (1999) 1.57
Impact of deprivation and rural residence on treatment of colorectal and lung cancer. Br J Cancer (2002) 1.55
Disulfiram modulated ROS-MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties. Br J Cancer (2011) 1.53
Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer (2001) 1.52
Congestion of right liver graft in living donor liver transplantation. Transplantation (2001) 1.51
Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol (2007) 1.50
Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer (2002) 1.49
Severe impairment of salivation in Na+/K+/2Cl- cotransporter (NKCC1)-deficient mice. J Biol Chem (2000) 1.49
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol (2003) 1.48
Inhibition of epithelial cell apoptosis by Porphyromonas gingivalis. FEMS Microbiol Lett (2001) 1.47
Meal-induced peptide tyrosine tyrosine inhibition of pancreatic secretion in the rat. FASEB J (1989) 1.47
Paget's disease of the breast. Cancer (1970) 1.44
[Increased expression of hypoxia-inducible factor-1α and connective tissue growth factor accompanied by fibrosis in the rat testis of varicocele]. Actas Urol Esp (2012) 1.44
A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. Br J Cancer (2011) 1.44
Letter: Streptococcus milleri liver abscesses. Lancet (1976) 1.43
Laser capture microscopy. Mol Pathol (2000) 1.43
Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology (1999) 1.42
New transtracheal bronchoalveolar lavage technique for the diagnosis of respiratory disease in sheep. Vet Rec (2005) 1.41
Evidence for an immune complex vasculitis in neonatal necrotising enterocolitis. J Clin Pathol (1981) 1.39
Bayesian analysis of pentaquark signals from CLAS data. Phys Rev Lett (2008) 1.39
Systematic review of cancer treatment programmes in remote and rural areas. Br J Cancer (1999) 1.39
A bacteriological study of the immediate environment of a surgical wound. Br J Surg (1971) 1.38
Tricyclic antidepressant fatality: postmortem tissue concentrations. J Toxicol Clin Toxicol (2001) 1.38
Measurement of two- and three-nucleon short-range correlation probabilities in nuclei. Phys Rev Lett (2006) 1.37
Effect of marihuana and placebo-marihuana smoking on angina pectoris. N Engl J Med (1974) 1.34
Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. J Histochem Cytochem (1999) 1.33
Regulation of transforming growth factor-beta 1 expression by the hepatitis B virus (HBV) X transactivator. Role in HBV pathogenesis. J Clin Invest (1996) 1.33
CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma? Ann Oncol (2001) 1.32
Epidemiology and outcome of acute pancreatitis. Br J Surg (1987) 1.32
Proteomics: a new approach to the study of disease. J Pathol (2000) 1.32
Cocaine-induced cortical microischemia in the rodent brain: clinical implications. Mol Psychiatry (2011) 1.31
Identification of a transcriptional initiator element in the cytochrome c oxidase subunit Vb promoter which binds to transcription factors NF-E1 (YY-1, delta) and Sp1. J Biol Chem (1993) 1.31
Surface modification of polymeric biomaterials with poly(ethylene oxide), albumin, and heparin for reduced thrombogenicity. J Biomater Sci Polym Ed (1993) 1.31
Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer (2009) 1.30
Marrow-derived cells populate scaffolds composed of xenogeneic extracellular matrix. Exp Hematol (2001) 1.29
Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status. AJNR Am J Neuroradiol (2011) 1.29
Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer. J Clin Pathol (2002) 1.27
Phase I and pharmacokinetic study of rhizoxin. Cancer Res (1992) 1.26
Induction of glucose-regulated protein 78 by chronic hypoxia in human gastric tumor cells through a protein kinase C-epsilon/ERK/AP-1 signaling cascade. Cancer Res (2001) 1.25
Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer (2009) 1.25
Phase I and pharmacokinetic study of flavone acetic acid. Cancer Res (1987) 1.24
Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther (2001) 1.24
Comparative genomic hybridization and chromosomal instability in solid tumours. Br J Cancer (1999) 1.24
Attitudes and practice in the management of metastatic colorectal cancer in Britain. Colorectal Cancer Working Party of the UK Medical Research Council. Clin Oncol (R Coll Radiol) (1997) 1.24
Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. Ann Oncol (2011) 1.24
Is juvenile obsessive-compulsive disorder a developmental subtype of the disorder? A review of the pediatric literature. J Am Acad Child Adolesc Psychiatry (1998) 1.23
beta-Cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus. Transplantation (2001) 1.22
The intracisternal A-particle upstream element interacts with transcription factor YY1 to activate transcription: pleiotropic effects of YY1 on distinct DNA promoter elements. Mol Cell Biol (1993) 1.21
Unnatural conceptions: the study of monsters in sixteenth- and seventeenth-century France and England. Past Present (1981) 1.21
Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res (1998) 1.21